![]() VIARTIS
|
||||||||||||
|
|
PARKINSON'S DISEASE NEWS
|
|
||||||||||
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail mail@viartis.net.
LOW RESOLUTION VERSION : There is a low resolution version of this web page INTENDED FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, or have eyesight difficulties, or have slow INTERNET SPEEDS. GO TO LOW RESOLUTION VERSION
21st May 2013 - New research PEPPERS REDUCE THE RISK OF PARKINSON'S DISEASE Annals of Neurology [2013] May 9 [Epub ahead of print] (Nielsen SS, Franklin GM, Longstreth WT, Swanson PD, Checkoway H.) Complete abstract Nicotine has long been known to reduce the risk of Parkinson's Disease. So researchers assessed whether the risk of Parkinson's Disease is associated with the consumption of nicotine-containing vegetables edibles from the same botanical family as tobacco, Solanaceae, which includes peppers, tomatoes, and potatoes.
Consumption of other vegetables was unrelated to the likelihood of developing Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
17th May 2013 - New research PRELADENANT CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders [2013] Apr 15 [Epub ahead of print] (S.A.Factor, K.Wolski,
D.M.Togasaki, S.Huyck, M. Cantillon, T.W.Ho, R.A.Hauser, E.Pourcher)
Complete abstract
3rd May 2013 - New research IS GENERIC MADOPAR AS GOOD AS MADOPAR ? BMC Pharmacology and Toxicology [2013] 14 (1) : 24 (U.E.Gasser, A.Fischer, J.P.Timmermans, I.Arnet) Complete abstract Madopar was compared against seven generic versions of Madopar to see if they were as good as Madopar. Madopar, which is for the treatment of Parkinson's Disease consists of L-dopa and benserazide, which helps to prevent the breakdown of L-dopa before it is made use of. It is therefore the equivalent of Sinemet. Madopar and Sinemet differ according to which countries they are available in. For more information go to Madopar. A generic version is supposed to be interchangeable. However, generic versions are often different from the original.
27th April 2013 - New research HEAD INJURY AND THE RISK OF PARKINSON'S DISEASE
Movement Disorders [2013] Apr 22 [Epub ahead of print] (S.Jafari, M.Etminan,
F.Aminzadeh, A.Samii)
Complete abstract
26th April 2013 - New bookHANDBOOK OF PARKINSON'S DISEASE (Fifth edition) Rajesh Pahwa (Editor), Kelly E. Lyons (Editor)
20th April 2013 - News release NEURTURIN FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Neurturin has failed to demonstrate any effect in Parkinson's Disease. Neurturin is administered using CERE-120, which is composed of a harmless adeno-associated virus (AAV) vector, which carries the gene for neurturin. Neurturin, which is naturally occurring, is known to repair damaged and dopamine-secreting neurons by restoring their function. Neurturin is a member of the same protein family as GDNF. CERE-120 is delivered by injection in to the brain. CERE-120 is produced by Ceregene Inc.
18th April 2013 - New researchBRAIN CELL LOSS IN PARKINSON'S DISEASE JAMA Neurology [2013] 70 (2) : 241-247 (D.A.Ziegler, J.S.Wonderlick, P.Ashourian, L.A.Hansen, J.C.Young, A.J. Murphy, C.K.Koppuzha, J.H.Growdon, S.Corkin) Complete abstract
Researchers assessed the volume of the brain in the area in which dopaminergic neurons are common. They found that the volume of the brain in this area was decreased in people with mild Parkinson's Disease but not in people that did not have Parkinson's Disease. However, in more severe Parkinson's Disease there was no greater loss of volume of the brain in the area affected by Parkinson's Disease as there would have been if the severity of Parkinson's Disease was due to cell loss. Research has always instead been consistent with a major reduction in cell activity rather than an actual loss of the cells involved in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
16th April 2013 - New bookDEFYING DEMENTIA Kevin Davies
13th April 2013 - New review TECHNOLOGICAL DEVICES FOR PARKINSON'S DISEASE (Part 1) In recent years technological devices have started being used to try to improve or aid people with Parkinson's Disease without the necessity for drugs or surgery : LIGHT THERAPY consists of daily exposure to daylight, brighter artificial light, or to specific wavelengths of light. Light suppresses melatonin formation, which lowers dopamine activity. For more information go to Light therapy. LASER DEVICES, including laser lights attached to canes, handheld devices or the Parkinson walkers. They display a beam of light on the ground, providing a target to step over to help overcome freezing episodes. For more information go to Laser cane and Laser Walker. FUNCTIONAL ELECTRICAL STIMULATION is the use of electrical impulses to stimulate weak or paralysed muscles. For more information go to Functional electrical stimulation. FOCUSED ULTRASOUND uses multiple intersecting beams of ultrasound energy are focused with a high degree of precision and accuracy on the target. For more information go to Focused Ultrasound. MAGNETIC THERAPY involves the use of an extremely low-level electromagnetic field applied by a specially designed device, the Magnesphere. Helmholtz coils immerse the entire patient in a low strength electromagnetic field. For more information go to Magnetic therapy. For a printable version of this article click here. In order to refer to this article on its own click here.
12th April 2013 - New web site THE PARKINSON HUB
6th April 2013 - New research ISTRADEFYLLINE CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders [2013] Mar 11 [Epub ahead of print] (Y.Mizuno, T.Kondo, the
Japanese Istradefylline Study Group.
Complete abstract
5th April 2013 - New bookAVOID 1-CLICK SHOPPING IF YOU HAVE PARKINSON'S C. Michael Beetner
1st April 2013 - New research INHALED DOPAMINE AGONIST CLINICAL TRIAL RESULTS
Acta Neurologica Scandinavica [2013] Mar 26 [Epub ahead of print] (K.A.Grosset,
N.Malek, F.Morgan, D.G. Grosset)
Complete abstract
30th March 2013 - New bookPARKINSON'S TREATMENT : 10 SECRETS TO A HAPPIER LIFE Michael S.Okun MD
24th March 2103 - News release NEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVO A new L-dopa product, which is presently called ODM-101, significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias when compared to Stalevo, which is a standard medication in advanced Parkinson's Disease when people experience end-of-dose wearing off symptoms using L-dopa. Stalevo contains three active substances in one tablet : L-dopa, plus carbidopa and entacapone, both of which help to maintain L-dopa levels. For more information go to Stalevo. ODM-101 has the same components as Stalevo but has a higher and fixed amount of carbidopa (either 65mg or 105 mg) regardless of the L-dopa dosage. As it made by the same manufacturers it is effectively an improved form of Stalevo.
23rd March 2013 - New research PIMAVANSERIN CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE In a phase III clinical trial, Pimavanserin had effect in the treatment of psychosis in Parkinson's Disease. Parkinson’s Disease Psychosis usually consists of visual hallucinations and delusions. It is normally due to Parkinson's Disease drugs not Parkinson's Disease. It eventually occurs in up to 60% of people with Parkinson's Disease. Pimavanserin is an antagonist of serotonin 5-HT2A receptors. It is taken orally as a tablet once-a-day.
14th March 2013 - New research BEING OVERWEIGHT IS MORE PREVALENT IN PARKINSON'S DISEASE Arquivos de Neuropsiquiatra [2012] 70 (11) : 843-846 (H.Morales-Briceño, A.Cervantes-Arriaga, M.Rodríguez-Violante, J.Calleja-Castillo, T.Corona) Complete abstract
5th March 2013 - News release CLINICAL TRIAL OF SUBCUTANEOUS L-DOPA FOR PARKINSON'S DISEASE
ND0612 is a combination of L-dopa and carbidopa, as is Sinemet, but it is a liquid formula administered continuously sub-cutaneously (via the skin) through a patch pump. It is designed to provide steady L-dopa blood levels for the reduction of motor complications in Parkinson’s Disease. In this double-blind, placebo controlled, dose-escalation trial in young, healthy volunteers, ND0612 was shown to be safe and tolerable in all of the tested doses. Clinically meaningful L-dopa concentrations were reached. For the first time in humans, steady state L-dopa concentrations were maintained in a practical manner both day and night, thereby enabling more even levels of L-dopa than oral forms of L-dopa. The full results of this study will be presented at a future scientific meeting. For more information go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
4th March 2013 - New book HOW TO LIVE WELL WITH PARKINSON'S : ADVICE FROM A PHYSICAL THERAPIST Miriam P. Boelen
3rd March 2013 - New survey SURVEY OF THE CAUSES OF PARKINSON'S DISEASE
18th February 2013 - News release COGANE FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Phytopharm announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated patients with early-stage Parkinson’s Disease. Cogane was found to have no beneficial effects at all on Parkinson's Disease symptoms. For more information go to the News release
15th February 2013 - New research DBS IS EFFECTIVE IN EARLIER PARKINSON'S DISEASE
New England Journal of Medicine [2013] 368 (7) : 610-622 (Schuepbach WM, Rau J,
Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM,
Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A,
Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel
Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D,
Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker
MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A,
Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM
Study Group)
Complete abstract In a two year clinical trial people with Parkinson's Disease and early motor complications (with an average age of 52 and a mean duration of Parkinson's Disease of 7.5 years) underwent neurostimulation plus medical therapy or only medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) with scores ranging from 0 to 100 and higher scores indicating worse function. For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points. Neurostimulation was superior to medical therapy with respect to motor disability, activities of daily living, L-dopa induced motor complications, and time with good mobility and no dyskinesia. Serious adverse events occurred in 54% of the people in the neurostimulation group and in 44% of those in the medical therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17% of people. For a printable version of this article click here. In order to refer to this article on its own click here.
14th February 2013 - New research MOLECULAR HYDROGEN WATER FOR PARKINSON'S DISEASE Movement Disorders [2013] Feb 11 (A.Yoritaka, M.Takanashi, M.Hirayama, T.Nakahara, S.Ohta, N.Hattori, D.Weintraub, K.Papay, A.Siderowf) Complete abstract Oxidative stress is involved in the progression of Parkinson's Disease. Recent studies have confirmed that molecular hydrogen (H2) functions as a highly effective antioxidant in cultured cells and animals.
8th February 2013 - News release POSITIVE RESULTS CLAIMED FOR STEM CELLS IN PARKINSON'S DISEASE International Stem Cell Corporation have claimed positive results from its pre-clinical study using stem cells in the treatment of Parkinson's Disease. The primary goal of the study was to demonstrate the benefits of neuronal cells derived from human stem cells. The neuronal cells were derived from human parthenogenetic stem cells, which are not obtained via reproduction. They can become neurons when they are implanted in to the brain.
Although it was claimed for many years that stem cells could rid Parkinson's Disease, stem cell operations have not fulfilled those claims. It was widely believed that stem cell operations were essential because there was a massive loss of cells involved in Parkinson's Disease. However, no study has ever demonstrated massive cell loss in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
6th February 2013 - New book SO I'VE GOT PARKINSON'S DISEASE Terry Rummins
29th January 2013 - New research USING CELL PHONES TO MONITOR PARKINSON'S DISEASE IEEE Transactions on Biomedical Engineering (submitted) [2013] (A.Tsanas, M.A.Little, P.E.McSharry, L.O. Ramig) Complete abstract Dysphonia is an impairment in the ability to produce vocal sounds that can occur in Parkinson's Disease. A wide range of dysphonia measures have been used to predict Parkinson's Disease severity using speech signals. Researchers demonstrated that this method can match standard methods of diagnosing Parkinson's Disease.
This study investigated using the cellular mobile telephone networks for Parkinson's Disease monitoring. The Parkinson's Disease (UPDRS) symptom score could be estimated to within about 3.5 points difference from the clinicians’ assessment, which is useful because even different clinicians vary by as much as 4 to 5 points. This provides evidence that the phone network is adequate for inexpensive, mass-scale Parkinson's Disease symptom monitoring. For a printable version of this article click here. In order to refer to this article on its own click here.
28th January 2013 - New book THE ESSENTIAL DYSPHAGIA HANDBOOK : REAL LIFE DECISIONS, MINDMAPPING AND MORE Dr Claire Langdon, Karen Jardine, Dr Julie Cichero
12th January 2013 - New research PARKINSON'S DISEASE DOES NOT CAUSE COMPULSIONS Neurology [2013] 80 (2) : 176-180 (Weintraub D, Papay K, Siderowf A) Complete abstract Although compulsions can often occur in Parkinson's Disease, Parkinson's Disease does not actually cause compulsions or related problems. When people with Parkinson's Disease were compared with people who do not have Parkinson's Disease the frequencies of compulsions were little different : gambling (1.2% v 0.7%), buying (3% v 2%), sexual behaviour (4.2% v 3.5%), eating (7% v 10%), punding (prolonged, purposeless, and stereotyped behaviour) (5% v 2%), hobbyism (5% v 12%), walkabout (0.6% v 0.7%), any compulsions (18% v 20%). The fact that Parkinson's Disease itself does not seem to cause an increased risk of developing compulsions or related behaviour further reinforces the reported association between Parkinson's Disease drugs and causing compulsions. Given that approximately 20% of people with newly diagnosed Parkinson's Disease report some impulse control or related behaviour symptoms, long-term follow-up is needed to determine whether such people are at increased risk for impulse control disorder development once Parkinson's Disease drugs are initiated. For a printable version of this article click here. In order to refer to this article on its own click here.
11th January 2013 - News release SALIVA GLAND TEST FOR PARKINSON'S DISEASE New research has suggested that testing a portion of a person's saliva gland may be a means of diagnosing Parkinson's Disease. It was previously shown in autopsies of people with Parkinson's Disease that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, which are found under the lower jaw.
|
||||||||||||
|
||||||||||||
| GO TO DECEMBER 2012 | ||||||||||||
|
ARCHIVES 2012 : January February March April May June July August September October November December 2011 : January February March April May June July August September October November December March April May June July August September October November December March April May June July August September October November December2008 : January February March April May June July August September October November December |
||||||||||||
![]() |
||||||||||||
| ©2006-2011 Viartis | ||||||||||||
| mail@viartis.net | ||||||||||||